Patents by Inventor Lewis A. Phillips

Lewis A. Phillips has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-HER2 Antibodies and Immunoconjugates
    Publication number: 20230041134
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 14, 2022
    Publication date: February 9, 2023
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR
    Publication number: 20210213130
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Application
    Filed: December 21, 2020
    Publication date: July 15, 2021
    Applicant: GENENTECH, INC.
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • Combination therapy with an anti-HER2 antibody-drug conjugate and a Bcl-2 inhibitor
    Patent number: 10898570
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • Anti-HER2 Antibodies and Immunoconjugates
    Publication number: 20200255539
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: August 13, 2020
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Immunoconjugates Comprising Anti-HER2 Antibodies and Pyrrolobenzodiazepines
    Publication number: 20200085840
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: April 23, 2019
    Publication date: March 19, 2020
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 10556966
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-HER2 Antibodies and Immunoconjugates
    Publication number: 20190177429
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 13, 2019
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Immunoconjugates comprising anti-HER2 antibodies and pyrrolobenzodiazepines
    Patent number: 10314846
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 11, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 10179820
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR
    Publication number: 20180140700
    Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 24, 2018
    Inventors: Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
  • IMMUNOCONJUGATES COMPRISING ANTI-HER2 ANTIBODIES AND PYRROLOBENZODIAZEPINES
    Publication number: 20170274092
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 28, 2017
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20170174782
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 18, 2016
    Publication date: June 22, 2017
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 9518118
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20160096893
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 11, 2015
    Publication date: April 7, 2016
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20140140993
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Genentech, Inc.
    Inventors: Leanne Berry Ross, Gail Lewis Phillips, Mark X. Sliwkowski
  • Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
    Patent number: 8663643
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 4, 2014
    Assignee: Genentech, Inc.
    Inventors: Leanne Berry, Gail Lewis Phillips, Mark X. Sliwkowski
  • COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20120107302
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: March 10, 2009
    Publication date: May 3, 2012
    Inventors: Leanne Berry, Gail Lewis Phillips, Mark X. Sliwkowski
  • Apo-2 ligand-anti-Her-2 antibody synergism
    Publication number: 20080241146
    Abstract: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.
    Type: Application
    Filed: October 25, 2007
    Publication date: October 2, 2008
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gail Lewis Phillips
  • Apo-2 ligand-anti-her-2 antibody synergism
    Publication number: 20080160026
    Abstract: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.
    Type: Application
    Filed: October 25, 2007
    Publication date: July 3, 2008
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gail Lewis Phillips
  • Apo-2 ligand-anti-Her-2 antibody synergism
    Publication number: 20020141993
    Abstract: Methods of using synergistically effective amounts of Apo-2 ligand and anti-Her-2 antibodies to enhance cell death via apoptosis are provided.
    Type: Application
    Filed: March 26, 2002
    Publication date: October 3, 2002
    Applicant: GENENTECH, INC.
    Inventors: Avi J. Ashkenazi, Gail Lewis Phillips